|
pubmed:abstractText |
Several reports demonstrated that the activation of Nuclear Factor-kappa B NF-?B is essential for the pathogenesis of multiple myeloma (MM). We analyzed the nuclear localization of NF-?B in MM-cells derived from 60 different patients with MM at presentation and in relapse, as well as in three myeloma cell lines. Nuclear localization (the active form) of NF-?B was detected in only one MM-sample from a refractory patient and in two samples from relapsed patients, while all the other samples, including the MM-cell lines, almost exclusively express the cytoplasmic (inactive) form of NF-?B. In mesenchymal cells from MM-patients NF-?B was clearly present in the nucleus. In addition, the proteasome inhibitor Bortezomib, which is described to antagonize NF-?B activity, had a consistent antitumor activity against both chemoresistant and chemosensitive MM-cells, regardless the NF-?B localization, thus suggesting the existence of other molecular targets of proteasome inhibitors in MM.
|
